MetaCap

Cardiff Oncology (CRDF) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiff Oncology (CRDF) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 58.0% versus a loss of 76.7%. Over five years, CRDF leads with a -84.8% price change compared with -98.5% for TNYA. Cardiff Oncology is the larger company by market cap ($66.3 million vs $65.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDF-57.99%TNYA-76.70%
+65%-9%-83%
Nov 21, 20251 yearNov 20, 2026
CRDF-84.99%TNYA-98.68%
+27%-39%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDF versus TNYA key metrics
MetricCRDFTNYA
Share price$0.8528$0.2866
Market cap$66.34M$65.32M
1-day change-4.46%-3.99%
YTD return-69.65%-59.75%
1-year return-57.99%-76.70%
5-year return-84.80%-98.50%
EPS (TTM)$-0.54$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$593.00K—
Revenue growth (YoY)-13.18%—
Net income (latest FY)$-45.85M$-90.60M
Operating margin-8256.32%—
Net margin-7732.04%—
52-week high$3.31$1.46
52-week low$0.71$0.28
Distance from 52-week high-74.24%-80.37%
Analyst consensusnonenone
Avg. price target upside+581.29%+1016.54%
Average volume1.01M2.96M
Shares outstanding77.80M227.93M
Employees3070
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDF has outperformed TNYA by 18.7 percentage points over the past year.

About Cardiff Oncology

CRDF stock →

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

CRDF vs TNYA FAQ

Which is bigger, Cardiff Oncology or Tenaya Therapeutics?

Cardiff Oncology (CRDF) is larger, with a market capitalization of $66.34M compared with $65.32M for Tenaya Therapeutics (TNYA).

Which stock has performed better over the past year, CRDF or TNYA?

CRDF returned -57.99% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are Cardiff Oncology and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons